Unicycive Therapeutics Inc
UNCY | $1.08 -0.92% -0.93% 230K
|
Professional, Scientific, and T...
(0.0% 1d) (-23.2% 1m) (-32.3% 1y) (0.0% 2d) (-6.0% 3d) (-4.4% 7d) (550.49% volume)
Earnings Calendar: 2022-11-10
Market Cap: $ 37,536,951
https://unicycive.com
Sec Filling | Patents | 2021 employees
Unicycive is a biotechnology company developing novel treatment for kidney diseases. Unicycive's lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. UNI-494 is a patent protected new chemical entity in late preclinical development for the treatment of acute kidney injury.
treatment kidney
add to watch list Paper trade email alert is off
Press-releases
Unicycive Therapeutics to Present at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
Published: 2024-04-10 (Crawled : 11:00) - globenewswire.com
UNCY | $1.08 -0.92% -0.93% 230K
|
Professional, Scientific, and T...
|
| O: 0.0%
H: 0.0%
C: -1.52%
conference therapeutics growth
Unicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business Update
Published: 2024-03-28 (Crawled : 20:00) - globenewswire.com
UNCY | $1.08 -0.92% -0.93% 230K
|
Professional, Scientific, and T...
| Email alert
Add to watchlist
business year update financial results
Unicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association Congress
Published: 2024-03-25 (Crawled : 11:00) - globenewswire.com
UNCY | $1.08 -0.92% -0.93% 230K
|
Professional, Scientific, and T...
|
| O: 1.36%
H: 7.38%
C: 2.01%
congress association renal therapeutics
Unicycive Announces $50 Million Private Placement
Published: 2024-03-14 (Crawled : 11:00) - globenewswire.com
UNCY | $1.08 -0.92% -0.93% 230K
|
Professional, Scientific, and T...
|
| O: 8.63%
H: 14.57%
C: -4.64%
million
Unicycive Therapeutics Delivers Both an Oral and Poster Presentation on UNI-494 at the AKI and CRRT Conference
Published: 2024-03-13 (Crawled : 11:00) - globenewswire.com
UNCY | $1.08 -0.92% -0.93% 230K
|
Professional, Scientific, and T...
|
| O: 1.75%
H: 1.03%
C: -4.47%
uni-494 conference presentation therapeutics
Unicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC)
Published: 2024-03-07 (Crawled : 21:00) - globenewswire.com
UNCY | $1.08 -0.92% -0.93% 230K
|
Professional, Scientific, and T...
|
| O: -6.67%
H: 10.71%
C: 8.57%
trial therapeutics
Unicycive Therapeutics Announces Orphan Drug Designation Granted for UNI-494 by the U.S. Food and Drug Administration for the Prevention of Delayed Graft Function in Kidney Transplant Patients
Published: 2024-03-04 (Crawled : 12:00) - globenewswire.com
UNCY | $1.08 -0.92% -0.93% 230K
|
Professional, Scientific, and T...
|
| O: 1.25%
H: 2.46%
C: -8.02%
uni-494 drug kidney granted food designation therapeutics
Unicycive Therapeutics to Present Two Posters on Oxylanthanum Carbonate (OLC) at the Upcoming National Kidney Foundation Spring Clinical Meeting
Published: 2024-02-14 (Crawled : 12:00) - globenewswire.com
UNCY | $1.08 -0.92% -0.93% 230K
|
Professional, Scientific, and T...
|
| O: 3.81%
H: 7.34%
C: 6.42%
kidney spring meeting therapeutics
Unicycive Therapeutics Announces Both an Oral and Poster Presentation to be Delivered on UNI-494 at the Upcoming AKI and CRRT Conference
Published: 2024-01-29 (Crawled : 12:00) - globenewswire.com
UNCY | $1.08 -0.92% -0.93% 230K
|
Professional, Scientific, and T...
|
| O: 5.73%
H: 3.24%
C: 1.61%
uni-494 conference presentation therapeutics
Unicycive Therapeutics Issues Shareholder Letter to Highlight Corporate Progress and Key Upcoming Milestones
Published: 2024-01-23 (Crawled : 12:00) - globenewswire.com
UNCY | $1.08 -0.92% -0.93% 230K
|
Professional, Scientific, and T...
|
| O: 4.69%
H: 20.69%
C: 12.99%
key therapeutics
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Last 48 Hours Insiders Buying
RXO P 200000 | $19.37 2.32% 0.0% 1M
|
n/a
|
23:00
RKT P 380 | $11.68 1.3% 0.17% 1.9M
|
Finance
|
22:30
HROW P 29400 | $10.43 -3.87% -4.03% 680K
|
Health Technology
|
22:30
BCDA P 2750 | $0.377 -1.4% 97K
|
Health Technology
|
22:00
RMCF | $3.67 3.38% 3.27% 11K
|
Consumer Non-Durables
|
20:10